Investor Presentaiton
JLL - 9M'FY20 Financial Highlights
Revenue
Pharmaceuticals²
EBITDA
Particulars¹
9M'FY19 9M'FY20
•
YOY
■ Revenue at Rs 6,763 Crore, increase of 1% from Rs 6,725 Crore in 9M'FY19
Change (%)
Pharmaceuticals revenue at Rs 4,231 Crore, increased by 7% YoY,
contributing 62% to revenue
■
•
3,943
4,231
7%
Life Science Ingredients
2,633
2,356
(11%)
.
Drug Discovery & Development Solutions³
149
176
18%
Total Revenue from Operations
6,725
6,763
1%
Pharmaceuticals²
1,087
1,127
4%
Life Science Ingredients
344
313
(9%)
Drug Discovery & Development Solutions
19
39
108%
Unallocated Corporate Expenses
(27)
(40)
.
Reported EBITDA
1,423
1,438
1%
Adjusted EBITDA
1,432
1,512
6%
45
35
674
638
43.2
40.0
(5%)
(7%)
Exceptional Items
PAT
EPS
EBITDA Margins
Pharmaceuticals
27.6%
26.6%
Life Science Ingredients
13.1%
13.3%
Drug Discovery & Development Solutions
12.5%
22.0%
Reported EBITDA
21.2%
21.3%
Adjusted EBITDA
21.3%
22.4%
Geography Wise Revenue
1,859,537
3,447 3,765
895 849
525 613
India
North
America
Europe &
Japan
ROW
9M'FY19
19M'FY20
LSI revenue at Rs 2,356 Crore decreased 11% YoY, contributing 35% to
revenue
Drug Discovery & Development Solutions (DDDS) revenue at Rs 176
Crore, an increase of 18% YoY
Reported EBITDA flat at Rs 1,438 Crore as compared to Rs 1,423 Crore in
9M'FY19. EBITDA margin at 21.3% against 21.2% in 9M'FY19
•
•
Pharmaceuticals EBITDA at Rs 1,127 Crore a 4% increase YoY with a
margin of 26.6% as compared to 27.6% in 9M'FY19
LSI EBITDA at Rs 313 Crore as compared to Rs 344 Crore in 9M'FY19;
9M'FY20 margin at 13.3% as compared to 13.1% in 9M'FY19
DDDS EBITDA at Rs 39 Crore up from Rs 19 Crore in 9M'FY19; 9M'FY20
margin at 22% as compared with 12.5% in 9M'FY19
■ Adjusted EBITDA after one-off expenses at Rs 1,512 Crore vs. Rs 1,432 Crore
in 9M'FY19, growth of 6% YoY. Adjusted EBITDA margin in 9M was 22.4% vs.
21.3% in 9M'FY19
■ Finance costs at Rs 216 Crore as compared to Rs 158 Crore in 9M'FY19.
Exceptional charge of Rs 23 Crore related to prepayment of high yield bonds
and NCDs and Rs 11 Crore related to write-off of fixed assets not in use.
9M'FY19 charge of 45 Crore is related to IFC Stock settlement charge
■ Net Profit at Rs 638 Crore down 5% YoY. EPS of Rs 40.0 vs. Rs 43.2 in
9M'FY19
◉
Capex in 9M'FY20 of Rs 428 Crore
■ Net debt lower by Rs 217 Crore during 9M'FY20
1. All figures are in Rs Crore unless otherwise stated
123
2.
3.
Pharmaceuticals segment includes India Branded Pharmaceuticals business under the Generics segment
Drug Discovery & Development Solutions include the Drug Discovery Services (Biosys & Chemsys) business and Proprietary Drug Discovery business (Jubilant Therapeutics)
JUBILANT
LIFESCIENCESView entire presentation